Literature DB >> 23161457

MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1.

Vincent Huin1, Francis Vasseur, Susanna Schraen-Maschke, Claire-Marie Dhaenens, Patrick Devos, Kathy Dupont, Nicolas Sergeant, Luc Buée, Arnaud Lacour, Hélène Hofmann-Radvanyi, Bernard Sablonnière.   

Abstract

Myotonic dystrophy type 1 (DM1) is a multisystemic autosomal dominant disorder characterized by a highly variable phenotype and caused by an unstable CTG repeat expansion in the 3' untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Longer CTG repeat expansions often correlate with an anticipated age at onset and CTG repeat number may account for 45-60 % of the variance in disease severity. In order to search for candidate genes that could act as modifiers of disease severity, we studied the association between Muscleblind-like protein-1 (MBNL1) gene polymorphisms and the DM1 phenotype. In a group of 301 patients diagnosed with DM1 based on clinical symptoms, diagnosis was confirmed by molecular analysis of the DMPK gene. Patients were divided into four subtypes. The first subtype corresponded to asymptomatic patients or those with a mild phenotype, the second included those with a classic phenotype, the third concerned childhood onset, and the fourth corresponded to the congenital form of DM1. Three SNPs located in the MBNL1 gene promoter, rs323622, rs17283597, and rs17433672, were studied. Case-control analysis revealed that allele frequencies for the latter two were significantly associated with DM1 (p = 0.037 and p = 0.020). Multivariate linear regression analysis using phenotype as the dependent variable demonstrated that the TT genotype of the third SNP, rs323622, was associated with a more severe phenotype (p = 0.0034) and accounted for 1.88 % of the variance in disease severity. We report the association of several genetic variants of the MBNL1 gene with DM1 or with the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23161457     DOI: 10.1007/s00415-012-6740-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions.

Authors:  M-E Arsenault; C Prévost; A Lescault; C Laberge; J Puymirat; J Mathieu
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

2.  A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies.

Authors:  D A Tregouet; V Garelle
Journal:  Bioinformatics       Date:  2007-02-18       Impact factor: 6.937

3.  Monte Carlo tests for associations between disease and alleles at highly polymorphic loci.

Authors:  P C Sham; D Curtis
Journal:  Ann Hum Genet       Date:  1995-01       Impact factor: 1.670

4.  Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.

Authors:  Xiaoyan Lin; Jill W Miller; Ami Mankodi; Rahul N Kanadia; Yuan Yuan; Richard T Moxley; Maurice S Swanson; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2006-05-22       Impact factor: 6.150

5.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Jihae Shin; Yuan Yuan; Stuart G Beattie; Thurman M Wheeler; Charles A Thornton; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

6.  Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism.

Authors:  C Lavedan; H Hofmann-Radvanyi; P Shelbourne; J P Rabes; C Duros; D Savoy; I Dehaupas; S Luce; K Johnson; C Junien
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

7.  Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats.

Authors:  Yoshihiro Kino; Daisuke Mori; Yoko Oma; Yuya Takeshita; Noboru Sasagawa; Shoichi Ishiura
Journal:  Hum Mol Genet       Date:  2004-01-13       Impact factor: 6.150

8.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

9.  RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression.

Authors:  Ramesh S Yadava; Carla D Frenzel-McCardell; Qing Yu; Varadamurthy Srinivasan; Amy L Tucker; Jack Puymirat; Charles A Thornton; Owen W Prall; Richard P Harvey; Mani S Mahadevan
Journal:  Nat Genet       Date:  2007-12-16       Impact factor: 38.330

10.  Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy.

Authors:  H G Harley; S A Rundle; J C MacMillan; J Myring; J D Brook; S Crow; W Reardon; I Fenton; D J Shaw; P S Harper
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

View more
  8 in total

1.  Molecular genetic and clinical characterization of myotonic dystrophy type 1 patients carrying variant repeats within DMPK expansions.

Authors:  Jovan Pešović; S Perić; M Brkušanin; G Brajušković; V Rakočević-Stojanović; Dušanka Savić-Pavićević
Journal:  Neurogenetics       Date:  2017-09-23       Impact factor: 2.660

2.  MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.

Authors:  Marianne Goodwin; Apoorva Mohan; Ranjan Batra; Kuang-Yung Lee; Konstantinos Charizanis; Francisco José Fernández Gómez; Sabiha Eddarkaoui; Nicolas Sergeant; Luc Buée; Takashi Kimura; H Brent Clark; Joline Dalton; Kenji Takamura; Sebastien M Weyn-Vanhentenryck; Chaolin Zhang; Tammy Reid; Laura P W Ranum; John W Day; Maurice S Swanson
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

3.  Parental age effects, but no evidence for an intrauterine effect in the transmission of myotonic dystrophy type 1.

Authors:  Fernando Morales; Melissa Vásquez; Patricia Cuenca; Domingo Campos; Carolina Santamaría; Gerardo Del Valle; Roberto Brian; Mauricio Sittenfeld; Darren G Monckton
Journal:  Eur J Hum Genet       Date:  2014-07-23       Impact factor: 4.246

4.  Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila.

Authors:  Estefania Cerro-Herreros; Juan M Fernandez-Costa; María Sabater-Arcis; Beatriz Llamusi; Ruben Artero
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

Review 5.  DM1 Phenotype Variability and Triplet Repeat Instability: Challenges in the Development of New Therapies.

Authors:  Stéphanie Tomé; Geneviève Gourdon
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

6.  tappAS: a comprehensive computational framework for the analysis of the functional impact of differential splicing.

Authors:  Lorena de la Fuente; Ángeles Arzalluz-Luque; Manuel Tardáguila; Héctor Del Risco; Cristina Martí; Sonia Tarazona; Pedro Salguero; Raymond Scott; Alberto Lerma; Ana Alastrue-Agudo; Pablo Bonilla; Jeremy R B Newman; Shunichi Kosugi; Lauren M McIntyre; Victoria Moreno-Manzano; Ana Conesa
Journal:  Genome Biol       Date:  2020-05-18       Impact factor: 13.583

7.  Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.

Authors:  Emma Bondy-Chorney; Tara E Crawford Parks; Aymeric Ravel-Chapuis; Roscoe Klinck; Lynda Rocheleau; Martin Pelchat; Benoit Chabot; Bernard J Jasmin; Jocelyn Côté
Journal:  PLoS Genet       Date:  2016-01-29       Impact factor: 5.917

8.  Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy.

Authors:  Estefanía Cerro-Herreros; Irene González-Martínez; Nerea Moreno-Cervera; Sarah Overby; Manuel Pérez-Alonso; Beatriz Llamusí; Rubén Artero
Journal:  Mol Ther Nucleic Acids       Date:  2020-07-21       Impact factor: 8.886

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.